Qube Research & Technologies (QRT)
CYTK icon

Qube Research & Technologies (QRT)’s Cytokinetics CYTK Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,800
Closed -$484K – 4540
2023
Q4 		$484K Buy
+5,800
New +$210K ﹤0.01% 2307

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CYTK Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Cytokinetics (CYTK) stake by 27% in Q2 2026, selling an estimated $14.9M and leaving 572,535 shares worth $48.8M. The position accounts for 0.05% of the portfolio, ranked #506.

Qube Research & Technologies (QRT) first reported a position in CYTK in Q2 2020 and has held it in 16 quarters since. The position peaked at $51.4M in Q1 2026. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Qube Research & Technologies (QRT) held 572,535 shares of Cytokinetics worth $48.8M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 206,911 Cytokinetics shares in Q2 2026, an estimated $14.9M.
  • Cytokinetics made up 0.05% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #506 holding.
  • Qube Research & Technologies (QRT) first reported a position in Cytokinetics in Q2 2020 and has held it in 16 quarters since.
  • Qube Research & Technologies (QRT)'s Cytokinetics position peaked at $51.4M in Q1 2026.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.